UP!

AXGN $70   View long term graphs

AxoGen is a human tissue company based in Alachua, Florida making products to remedy peripheral nerve damage. In 2013 the company raised $18 million in its Initial Public Offering (IPO). AxoGen uses a cell graft technology AVANCE to mimic a human nerve. The company reports recovery in 87 percent of patients with peripheral nerve injuries. AxoGen is part of the Sid Martin Biotechnology Incubator.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-26 Future report Set alerts
Q2 2020 2020-08-05 -0.15 -0.20
Q1 2020 2020-05-06 -0.19 -0.21
Q4 2019 2020-02-24 -0.10 -0.18
Q3 2019 2019-11-06 -0.07 -0.14
Q2 2019 2019-08-06 -0.10 -0.18
Q1 2019 2019-05-08 -0.15 -0.24
Q4 2018 2019-02-26 -0.09 -0.13
Q3 2018 2018-10-29 -0.05 -0.11
Q2 2018 2018-08-01 -0.09 -0.20

Ratings

2016-05-05 Reiterated Rating Wedbush Outperform $7.50
2016-03-01 Reiterated Rating Wedbush Outperform $7.50
2015-11-06 Boost Price Target Wedbush $5.00 to $7.50
2015-11-06 Boost Price Target JMP Securities Market Outperform $5.50 to $8.00
2015-08-27 Reiterated Rating Wedbush Outperform $5.00
2015-04-01 Downgrade Langenberg & Company Hold
2015-04-01 Downgrade Ladenburg Thalmann Buy to Neutral $5.50 to $3.75
2015-03-12 Initiated Coverage Wedbush Outperform $5.00
2014-11-26 Initiated Coverage Lake Street Capital Buy
2014-11-25 Initiated Coverage Lake Street Capital Buy $4.00
2014-05-14 Initiated Coverage Dawson James Buy $5.00
2013-10-31 Boost Price Target Ladenburg Thalmann Buy $4.50 to $5.75
2016-05-05 Reiterated Rating Wedbush Outperform $7.50
2016-03-01 Reiterated Rating Wedbush Outperform $7.50
2015-11-06 Boost Price Target Wedbush $5.00 to $7.50
2015-11-06 Boost Price Target JMP Securities Market Outperform $5.50 to $8.00
2015-08-27 Reiterated Rating Wedbush Outperform $5.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Essex Woodlands Fund IX, L.P. 21.25%  (3711111) AXGN / PSDV /
NEELS GUIDO J 19.30%  (3371111) AXGN / ELGX /
Flynn James E Possible Member of 10% Group 17.18%  (3000000) AAVL / ALIM / ASPX / ATRS / AUXL / AXGN / CASM / CYCC / DRNA / EHTH / EMAG / FIXX / HITK / LOXO / NURO / PRTO / REPH / RIGL / STRM / TRGT / TWTI / VNDA / XNPT /
Mandato Joseph M 7.02%  (1226773) AXGN /
Hopfenspirger Larry 2.44%  (426066) AXGN /
Gold Mark Stephen 2.06%  (360248) AXGN /
Zaderej Karen L. Chief Executive Officer 1.62%  (282147) AXGN /
Harper John Frederick 1.23%  (214094) AXGN /
Freitag Gregory Gene CEO, CFO 0.92%  (160865) AXGN / PBIO /
Hansen David K Corporate Controller 0.25%  (43792) AXGN /
MCCARREY SHAWN F SVP of Sales 0.25%  (43057) AXGN /
Donovan Michael Patrick Vice President, Operations 0.22%  (37617) AXGN /
Johnston Lee Robert Jr Chief Financial Officer 0.14%  (25000) AXGN /
Rudelius Robert James 0.13%  (23273) AXGN /
Schiaparelli Jill F SVP, Bus. Strategy&Marketing 0.07%  (12750) AXGN /
Friedman Mark Louis Vice President of RA/QA 0.03%  (5665) AXGN /
DeVinney Erick Wayne See Remarks 0.03%  (4659) AXGN /

Comments